Key points are not available for this paper at this time.
In patients with stage IB to IIIA EGFR mutation-positive NSCLC, disease-free survival was significantly longer among those who received osimertinib than among those who received placebo. (Funded by AstraZeneca; ADAURA ClinicalTrials.gov number, NCT02511106.).
Building similarity graph...
Analyzing shared references across papers
Loading...
Yi‐Long Wu
Masahiro Tsuboi
Jie He
New England Journal of Medicine
University of California, Los Angeles
University of Toronto
Shanghai Jiao Tong University
Building similarity graph...
Analyzing shared references across papers
Loading...
Wu et al. (Sat,) studied this question.
www.synapsesocial.com/papers/69d1ba57c1780f2df99203b7 — DOI: https://doi.org/10.1056/nejmoa2027071